Advanced search    

Search: authors:"Pieter Jelle Visser"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment

Background Amyloid pathology in subjects with mild cognitive impairment (MCI) is an important risk factor for progression to dementia due to Alzheimer’s disease. Predicting the onset of dementia is challenging even in the presence of amyloid, as time to progression varies considerably among patients and depends on the onset of neurodegeneration. Survival analysis can account for ...

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

Background We sought to define a cutoff for β-amyloid 1–42 in cerebrospinal fluid (CSF), a key marker for Alzheimer’s disease (AD), with data-driven Gaussian mixture modeling in a memory clinic population. Methods We performed a combined cross-sectional and prospective cohort study. We selected 2462 subjects with subjective cognitive decline, mild cognitive impairment, AD-type ...

The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group

. van der Flier 4 9 Pieter Jelle Visser 4 7 Stefano F. Cappa 4 5 14 0 IRCCS Fondazione Santa Lucia , via Ardeatina 354, Rome , Italy 1 Niccolò Cusano University , via Don Carlo Gnocchi, 3, Rome , Italy 2

Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review

Background Accurate identification of individuals at high risk of dementia influences clinical care, inclusion criteria for clinical trials and development of preventative strategies. Numerous models have been developed for predicting dementia. To evaluate these models we undertook a systematic review in 2010 and updated this in 2014 due to the increase in research published in ...

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice

Biomarkers: Implications for Clinical Practice Stephanie J. B. Vos Pieter Jelle Visser Frans Verhey Pauline Aalten Dirk Knol Inez Ramakers Philip Scheltens Marcel G. M. Olde Rikkert Marcel M. Verbeek

Can novel therapeutics halt the amyloid cascade?

The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunotherapy with bapineuzumab, a humanized anti-Aβ monoclonal antibody directed against the N-terminus of Aβ. This trial showed no differences within dose cohorts on the primary ...

Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort

Objectives To understand the relation between risk genes for Alzheimer’s disease (AD) and their influence on biomarkers for AD, we examined the association of AD in the Finnish cohort with single nucleotide polymorphisms (SNPs) from top AlzGene loci, genome-wide association studies (GWAS), and candidate gene studies; and tested the correlation between these SNPs and AD markers ...